Acute Myocardial Infarction and Acute Cerebral Infarction (AMIAC) Registry and Follow-up

Myocardial Infarction Clinical Trial

— AMIAC  

Official title:

The Registry and Follow-up of Patients With Acute Myocardial Infarction or Acute Cerebral Infarction

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03166696
• Other study ID #: 20170309
• Status: Active, not recruiting
• Phase: N/A
• First received: May 18, 2017
• Last updated: May 24, 2017
• Start date: January 3, 2000
• Est. completion date: May 2018

Study information

• Verified date: May 2017
• Source: Guangdong General Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

A registry of consecutive patients who were admitted and diagnosed with acute myocardial infarction or acute cerebral infarction were conducted at the Guangdong General Hospital or the First Affiliated Hospital of Guangzhou University of Chinese Medicine, Yue Bei People's Hospital, China, between January 2000 and December 2016. The adverse clinical outcomes, including all-cause mortality, were followed from the date of admission for acute myocardial infarction or acute cerebral infarction until study end (December 31, 2016). All-cause mortality, including the date of death, was identified from the electronic hospitalization data, phone follow-up, and confirmed by the household registration (HUKOU) system, a record of registration required by law in China. Baseline characteristics, including major treatment of acute myocardial infarction or acute cerebral infarction, estimated glomerular filtration rate (eGFR) and proteinuria, were collected. Demographic data were determined from the electronic hospitalization data and electronic hospital discharge records. All comorbid conditions were identified using International Statistical Classification of Diseases, Tenth Revision (ICD-10), coding algorithms applied to electronic physician claims and electronic hospital discharge records. Life style (smoking), treatment regimen at discharge, including angiotensin-converting enzyme inhibitor (ACEI), angiotensin II receptor blocker (ARB), were determined from the electronic hospitalization data.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 30000
• Est. completion date: May 2018
• Est. primary completion date: May 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• consecutive patients who were admitted and diagnosed with acute myocardial infarction or acute cerebral infarction

Exclusion Criteria:

• lacunar infarction

Related Conditions & MeSH terms

• Cerebral Infarction
• Chronic Kidney Diseases
• Infarction
• Kidney Diseases
• Mortality
• Myocardial Infarction
• Renal Insufficiency, Chronic

Locations

Country	Name	City	State
China	Guangdong General Hospital	Guangzhou	Guangdong
China	the First Affiliated Hospital of Guangzhou University of Chinese Medicine	Guangzhou	Guangdong
China	Yue Bei People's Hospital	Shaoguan	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
Guangdong General Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	all-cause mortality	all-cause mortality	follow up until the study end (May 2018,Anticipated)
Secondary	kidney outcome	ESRD or 50%eGFR decline	follow up until the study end (May 2018,Anticipated)